Dr. Mannino is an internationally recognized expert in the use of artificial lipid-based structures for the formulation and delivery of biologicals and pharmaceuticals, and has pioneered the use of cochleate technology for this purpose. He is a co-inventor of the proprietary, disruptive lipid-crystal nano-particle cochleate technology utilized by Matinas BioPharma to encapsulate existing drugs, making them safer, more tolerable, less toxic and orally available. Dr. Mannino has been a member of Matinas BioPharma’s Scientific Advisory Board since January 2015 and was an Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School from 1990 until August 2015.

 

Previously, Dr. Mannino was the founder of BioDelivery Sciences, Inc., and served as its President, Chief Executive Officer and Chief Scientific Officer and as a member of its Board of Directors from 1995 to 2000, when it was acquired by BioDelivery Sciences International, Inc. (BDSI). He served as BDSI’s Executive Vice President and Chief Scientific Officer from 2001 to 2009, and was a member of its Board of Directors from 2000 to 2007. In addition to his experience at BDSI, Dr. Mannino was an Assistant, then Associate Professor, at Albany Medical College from 1980 to 1990, and an Instructor then Assistant Professor at Rutgers Medical School from 1977 to 1980. He completed his postdoctoral training from 1973 to 1976 at the Biocenter in Basel, Switzerland and received his Ph.D. in Biological Chemistry in 1973 from the Johns Hopkins University, School of Medicine.

Recent Posts

Forward Looking Statements

Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect our business, particularly those identified in the risk factor and cautionary factors discussions in our SEC filings. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. We specifically disclaim obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date.

This Blog is official and sanctioned by Matinas BioPharma Holdings | See Forward Looking Statements | See Privacy Policy | See Terms of Use

Get Matinas BioPharma Holdings Blog Post Alerts